<SEC-DOCUMENT>0001385155-26-000004.txt : 20260318
<SEC-HEADER>0001385155-26-000004.hdr.sgml : 20260318
<ACCEPTANCE-DATETIME>20260318142323
ACCESSION NUMBER:		0001385155-26-000004
CONFORMED SUBMISSION TYPE:	3
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20260318
FILED AS OF DATE:		20260318
DATE AS OF CHANGE:		20260318

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Meeker David P
		CENTRAL INDEX KEY:			0001385155
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		3
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40010
		FILM NUMBER:		26768002

	MAIL ADDRESS:	
		STREET 1:		C/O RHYTHM PHARMACEUTICALS
		STREET 2:		222 BERKELEY STREET, SUITE 1200
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Pharvaris N.V.
		CENTRAL INDEX KEY:			0001830487
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		J.H. OORTWEG 21
		STREET 2:		2333 CH LEIDEN
		CITY:			LEIDEN
		PROVINCE COUNTRY:   	P7
		BUSINESS PHONE:		31 (0)71 203 6410

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		J.H. OORTWEG 21
		STREET 2:		2333 CH LEIDEN
		CITY:			LEIDEN
		PROVINCE COUNTRY:   	P7

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Pharvaris, B.V.
		DATE OF NAME CHANGE:	20201029
</SEC-HEADER>
<DOCUMENT>
<TYPE>3
<SEQUENCE>1
<FILENAME>ownership.xml
<DESCRIPTION>3
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0607</schemaVersion>

    <documentType>3</documentType>

    <periodOfReport>2026-03-18</periodOfReport>

    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0001830487</issuerCik>
        <issuerName>Pharvaris N.V.</issuerName>
        <issuerTradingSymbol>PHVS</issuerTradingSymbol>
        <issuerForeignTradingSymbol></issuerForeignTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001385155</rptOwnerCik>
            <rptOwnerName>Meeker David P</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>1 CRANBERRY HILL SUITE 400</rptOwnerStreet1>
            <rptOwnerStreet2></rptOwnerStreet2>
            <rptOwnerCity>LEXINGTON</rptOwnerCity>
            <rptOwnerState>MA</rptOwnerState>
            <rptOwnerZipCode>02421</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>true</isDirector>
            <isOfficer>false</isOfficer>
            <isTenPercentOwner>false</isTenPercentOwner>
            <isOther>false</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>65167</value>
                    <footnoteId id="F1"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
    </nonDerivativeTable>

    <derivativeTable>
        <derivativeHolding>
            <securityTitle>
                <value>Stock Option (Right to Buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>28.00</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <value>2027-03-03</value>
                <footnoteId id="F2"/>
            </exerciseDate>
            <expirationDate>
                <value>2036-03-03</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>16500</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
        <derivativeHolding>
            <securityTitle>
                <value>Stock Option (Right to Buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>16.05</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <value>2026-03-12</value>
                <footnoteId id="F2"/>
            </exerciseDate>
            <expirationDate>
                <value>2035-03-12</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>15000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
        <derivativeHolding>
            <securityTitle>
                <value>Stock Option (Right to Buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>22.31</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <value>2025-04-11</value>
                <footnoteId id="F2"/>
            </exerciseDate>
            <expirationDate>
                <value>2034-04-11</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>14000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
        <derivativeHolding>
            <securityTitle>
                <value>Stock Option (Right to Buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>8.05</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F3"/>
            </exerciseDate>
            <expirationDate>
                <value>2033-04-06</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>21000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
        <derivativeHolding>
            <securityTitle>
                <value>Stock Option (Right to Buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>18.14</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F4"/>
            </exerciseDate>
            <expirationDate>
                <value>2032-04-01</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>17500</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
        <derivativeHolding>
            <securityTitle>
                <value>Stock Option (Right to Buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>7.89</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F5"/>
            </exerciseDate>
            <expirationDate>
                <value>2031-01-01</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>80000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">Includes restricted stock units previously granted under the Company's equity plan that remain outstanding as of March 18, 2026. The awards settle in shares of common stock and are reported in Table I as non-derivative securities. Vesting occurs as follows:
-5,500 RSUs from an award granted March 3, 2026 of which 100% will vest March 3, 2027.</footnote>
        <footnote id="F2">100% of the option vest on the 12-month anniversary.</footnote>
        <footnote id="F3">25% of the option vested on April 6, 2024 with the remaining shares vesting in 1/48 monthly installments thereafter.</footnote>
        <footnote id="F4">25% of the option vested on April 1, 2023 with the remaining shares vesting in 1/48 monthly installments thereafter.</footnote>
        <footnote id="F5">25% of the option vested on January 1, 2022 with the remaining shares vesting in 1/48 monthly installments thereafter.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Marnus Nel, Attorney-in-Fact for David Meeker</signatureName>
        <signatureDate>2026-03-18</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-24.POA
<SEQUENCE>2
<FILENAME>phvs-ex24_poa.htm
<DESCRIPTION>EX-24.POA
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-03-18T04:27:37.4300+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-24.POA</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.13in;z-index:2;min-height:0.93in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.187%;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><h1 style="font-size:10pt;margin-top:4.2pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.361%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">POWER OF ATTORNEY</font></h1><p style="margin-left:0.093%;font-size:10pt;margin-top:11.9pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.361%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 2, 2026</font></p><p style="text-indent:8.779%;font-size:10pt;margin-top:11.9pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.259%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">KNOW ALL BY THESE PRESENTS, that the undersigned hereby makes, constitutes and appoints each of David Nassif, Marnus Nel, and Skyler Wallace, acting individually, as the undersigned&#x2019;s true and lawful attorney-in-fact and agent, with full power and authority, including substitution and revocation, as hereinafter described on behalf of and in the name, place and stead of the undersigned to:</font></p><div class="item-list-element-wrapper" style="margin-left:1.204%;display:flex;margin-top:11.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:10%;min-width:5.463%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.529576096198226%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(i)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">execute for and on behalf of the undersigned, in the undersigned&#x2019;s capacity as a director, officer or beneficial owner of shares of stock of Pharvaris N.V., a Dutch public limited liability company (naamloze vennootschap) (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), any Schedule 13D or Schedule 13G, and any amendments, supplements or exhibits thereto (including any joint filing agreements) required to be filed by the undersigned under Section 13 of the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exchange</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Act</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), any Form 3, 4 and 5 and any amendments, supplements or exhibits thereto required to be filed by the undersigned under Section 16(a) of the Exchange Act, as well as notices on Form 144 and amendments thereto, filed pursuant to Rule 144 promulgated under the Securities Act of 1933, as amended (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Act</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;);</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.667%;display:flex;margin-top:12.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:9.87%;min-width:6%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.040288725801094%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seek or obtain, as the undersigned&#x2019;s representative and on the undersigned&#x2019;s behalf, information on transactions in the Company&#x2019;s securities from any third party, including brokers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such person to release any such information to any attorney-in-fact and further approves and ratifies any such release of information;</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:11.2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:9.87%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Schedule 13D, Schedule 13G, and any amendments thereto, Form 3, 4 or 5, and any amendments thereto, notices on Form 144 and amendments thereto, or any other required report relating to any of the foregoing and timely file such notices, forms or reports with the U.S. Securities and Exchange Commission and any stock exchange on which the stock of the Company is then listed; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.13%;display:flex;margin-top:6.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:9.87%;min-width:6.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.545509161910484%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iv)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorneys-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorneys-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorneys-in-fact may approve in each such attorney-in-fact&#x2019;s discretion.</font></div></div><p style="text-indent:8.785%;font-size:10pt;margin-top:11.9pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.315%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The undersigned hereby acknowledges that (a) the foregoing attorneys-in-fact are serving in such capacity at the request of the undersigned; (b) this Power of Attorney authorizes,</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.13in;z-index:2;min-height:0.93in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.187%;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.231%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">but does not require, each such attorney-in-fact to act in his or her discretion on information provided to such attorney-in-fact without independent verification of such information; (c) any documents prepared and/or executed by any attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such information and disclosure as such attorney-in-fact, in his or her sole discretion, deems necessary or advisable;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.25%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d) neither the Company nor any attorney-in-fact assumes (i) any liability for the undersigned's responsibility to comply with the requirements of the Exchange Act or Securities Act, as applicable, (ii) any liability of the undersigned for any failure to comply with such requirements,</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.241%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii) any obligation or liability of the undersigned for profit disgorgement under Section 16(b) of the Exchange Act, if applicable, or (iv) any liability resulting from a failure to qualify for the safe harbor under Rule 144; and (e) this Power of Attorney does not relieve the undersigned from responsibility for compliance with the undersigned&#x2019;s obligations under the Exchange Act or Securities Act, including, without limitation, the reporting requirements under Section 13 and Section 16 of the Exchange Act or Rule 144 promulgated under the Securities Act, as applicable.</font></p><p style="text-indent:8.78%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.269%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Power of Attorney shall remain in full force and effect (and shall survive, if necessary, by incapacity and/or death) until the undersigned is no longer required to file Schedule 13D or Schedule 13G, Forms 3, 4 or 5, notices on Form 144, or any amendments, supplements or exhibits to any of the foregoing with respect to the undersigned&#x2019;s holdings of, and transactions in, securities issued by the Company, unless earlier revoked as to any attorney-in-fact by the undersigned in a signed writing delivered to such attorney-in-fact.</font></p><p style="margin-left:0.12%;font-size:10pt;margin-top:12.3pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.361%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[Signature Page to Follow]</font></p><p style="margin-left:0.08%;font-size:10pt;margin-top:11.85pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.361%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* * * * *</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.13in;z-index:2;min-height:0.93in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.187%;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:6.734%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:1%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of the date first written above.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:53.333%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:1%;text-align:left;"><img src="img151619395_0.gif" alt="img151619395_0.gif" style="width:175px;height:70px;"></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img151619395_0.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img151619395_0.gif
M1TE&.#EA1@+J /<  /___P  ,P  9@  F0  S   _P S   S,P S9@ SF0 S
MS  S_P!F  !F,P!F9@!FF0!FS !F_P"9  "9,P"99@"9F0"9S "9_P#,  #,
M,P#,9@#,F0#,S #,_P#_  #_,P#_9@#_F0#_S #__S,  #, ,S, 9C, F3,
MS#, _S,S #,S,S,S9C,SF3,SS#,S_S-F #-F,S-F9C-FF3-FS#-F_S.9 #.9
M,S.99C.9F3.9S#.9_S/, #/,,S/,9C/,F3/,S#/,_S/_ #/_,S/_9C/_F3/_
MS#/__V8  &8 ,V8 9F8 F68 S&8 _V8S &8S,V8S9F8SF68SS&8S_V9F &9F
M,V9F9F9FF69FS&9F_V:9 &:9,V:99F:9F6:9S&:9_V;, &;,,V;,9F;,F6;,
MS&;,_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D S)D _YDS )DS
M,YDS9IDSF9DSS)DS_YEF )EF,YEF9IEFF9EFS)EF_YF9 )F9,YF99IF9F9F9
MS)F9_YG, )G,,YG,9IG,F9G,S)G,_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P
M,\P 9LP F<P S,P _\PS ,PS,\PS9LPSF<PSS,PS_\QF ,QF,\QF9LQFF<QF
MS,QF_\R9 ,R9,\R99LR9F<R9S,R9_\S, ,S,,\S,9LS,F<S,S,S,_\S_ ,S_
M,\S_9LS_F<S_S,S___\  /\ ,_\ 9O\ F?\ S/\ __\S /\S,_\S9O\SF?\S
MS/\S__]F /]F,_]F9O]FF?]FS/]F__^9 /^9,_^99O^9F?^9S/^9___, /_,
M,__,9O_,F?_,S/_,____ /__,___9O__F?__S/___P    8&!@P,#!,3$QD9
M&2 @("8F)BPL+#,S,SDY.4! 0$9&1DQ,3%-34UE966!@8&9F9FQL;'-S<WEY
M>8" @(:&AHR,C).3DYF9F:"@H*:FIJRLK+.SL[FYN<# P,;&QLS,S-/3T]G9
MV>#@X.;FYNSL[//S\_GY^2'Y! $     +     !& NH 1PC_  $('$BPH,&#
M"!,J7,BPH<.'$"-*G$BQHL6+&#-JW,BQH\>/($.*'$FRI,F3*%.J7,FRI<N7
M,&.^=):M9K8$"I'9K/DE83\D.V_.<L@I:+:>!T?MM&#PV3:; H8.%+53 4*:
M-A-(%:C3YH.M!)^1L!D@D4"E-I%RW8FTJTT=#*T!9=O0;;:R /K)V5G&(=J:
M.\[NC%K0&IZ=$!#:3;S6*UB9D"-+'BCH00($"2X_P)S P8#-#P8X2#"CQ8,H
M.5"COO+@2NH<5V9<J;!:=NH*L5VO;OTZ-VW8MJ/@#@Z[]8P9K0[:Q:GP;S;"
M (XA3KBW)EX 6&LR=DAJJ<%J<Y\__T98W>A=LP.72[5K]>#AM 35%^S'ABQZ
M %3-ZX>^^*!>OG[M!)=!<ME'4'G7%5C3 Y,UZ&!D7B 0FF>@"?+@1\GHI^%Y
M!TFW(53C%?4AAP2]-Z)X!95WXE$%9>A502:>J!8 +M;$'$$_&3B06"?>*-!_
M*V;35T/=!1G80889Y6-!V=UTX9-07I3 9IEA-EZ46&894HP;'JGE24UZ]^68
M9$+DV6B8(5+FFFRVZ>:;<,8) "(2BD::G'CFJ>>>?/9I4815)M"%GX06:NBA
MB&(YQI28(>!%HI"ZI(\I^41JZ:5M1@B:H%GJ-XXI"LGSC7GO8#H2/.;!8^JJ
MK#I(AH2<#?]ZX:@V"81/4*!"!$50I;:*T1X:XA.EAOKXJE$^-4%A+$N+4NBH
MEJ8$54)%0370YZY&];H1JCN%L],Z#9JCH3D Z!-4I<M.9%XXZ:+TJF67/8JE
M.D'-8Q&V-5G;KD/1[@0/LC;M,5DY08EKD[#EGBL1OC85:ZF&]^QKTKN-R@LE
MMS;E2I%1]4C,$*VU,CQ9/4&YL],W!1D%40D:1FJP>5 "G W*>9+1F9VR/FGN
M3AU/U.].$NFC@G[?1.R14<HVM+--XWC$L%'V2F;4K3;)8]#/-;&[T-+9"+O3
MM!6]'%0Z&5$-\T4:1IT1UT%EU'9"!.^D=C]ORV0SFIQ"*78V$JW_HW)#P :9
MC< &O?-W0^:IO= ]1KF#$<LGDBO9T_>(G9 \!2,DBTWH$,0K13$$1:]-8%>$
M=3;HX&H1YAQ#]([!1A-$\K=!]5S1.'4+=+B6[U9I<8-/VX3NUD:1C7B]!;&.
M]$*[%S1[LD%U?OQ.PS^4^D[: C"/>3$T&+W,V1BO$#@[@4/0R]4/!#[?$Y%O
ME/D9&9YX1LK7Y+"M^ED-@-GP&U0_]AK!'=">IC$R-0MG3Q)@R11R/9O0K"$@
MJPG"".*^;!0K@MF07$&V1SK5#<2# PG<P0:"C[C9I((U21]"GE>K@Z1C0QID
M"/BRQY$-101RG&L(XW9".(;H8P_N>$<[_X*BOXJP\&P6&=V(-!(4 V"D@1MZ
M8)MZAYF<76AOCBL(QEH(D?]E0Q8 .%U"-$3##]ID;RJDB-EV,D&"$- @X)-B
M04XW+I3@,!M%7,D66Y>0'9I'>@ 0H<(6$KR:Q"!7^D"A39*F$"6.2!ZQ>X@)
M@Q*.GMVC >:)84$4F"\\43%O9-I<\SQ&$#\FZXC9*!TI5\G*E%!L,[^#TL^^
M<;]6VO*6N'20IBYSIUSZ\I? Q.45.".A%@3SF,A,IJ]D$2C-*/.9T(QFH031
M*- ,P(JFRE%-AE28\)P(.@5QSH9HH)@/@;,@=C$/@Y@DN'42)$P?6A*/-M2>
MPG I*-<IC(KTL_\D "0IGN\4W  8HDTA+:03*QI04C9T3FF&Y%TF (T +(,9
M&6 AC6_""F$4-*.!6*,^!H7(/P=P)8PXIZ-%2HR'C*)0@KBHH03YIY<44HVQ
M9&.F$1%10[,#SOQD8SL[ HH#G* ?H 8U&P@@JGGJN9": H8A&AT*1PT")*U4
M)*H)$1%3' J95@A"$%[H@FEF(%8OM$"L79 -66> A;7&)JUO9:M;YYK6ML*5
MKG*]*UIG4,OH"$XH'IT+-Q^2G8XF!"OY; A:;N2B #PB(8O=2E=@VDT;(62>
MAE6()<CRV(1XZ"L)F6Q)KV*=^S3D&:4]"&85LM(56;4Q+&H(8M$S5?+_U*2E
M7,VM/P6+)-YFY)Z4/4@UGL)9A[0V&[B-SXHRBTX;C58@_W0M0L 3E.0*UZ8V
M&6Q"G$J7A72%I!91D'85LD\4.41%B36(3A^SWH*T5[?PC:]\YTO?^MKWOOA-
M"3Q'E-XUB?-#XVU2/_$$I&T&R"8XS:\R$8$%S&S*69D9C69X2:7.5(FBC(KP
MA2G,&0E+B,,:GK"#$]!7@:#6)@-MSF#Z$=B@J.6XH!U(F+:*G:  U3GN' AW
MG]/9],@H(37*1HZ+E!4=8Q<^ PER3?@3%/ .1$2I%8B*!,#B@1P7.CO.+G>,
MXLXLY[-)#85R8H/\@"HK^$M=H+  1M,"S,02_T]-2O%TC\S-'5-VGN;%,Y75
M:]Z!$%G(CP'S5ISS6N7L),8 D ^-=E+H'1UY1@)^3$'S"67D$O;0XREH2!E"
MZ/'H^3%VV8%=F'OF+YFF3A2*9*D-I: ^>TQ%I%YUE$[]@!:,1M:XSC5]1?,9
MS!10U\ .]C/3K)EG"?O8R XFH"J6[&8[NY6[K"*94+FA$JRCC?%=7]>>S>V.
M>.%FGL%F@^17$_B9LL0("1Y&@<E!HZ@J2P0S![:[?4M-,?M![E.;([.ACHF8
M;"?HUA.M\KB1?^O'0?" 0CCL);:G]1"9=\R&UO+K!3M)NU-!F?=#&-:]8+:[
M)O(0V60*V4*VK=N6^O]Y^'TUA4 LC1(BZ^OX+S.'0TW&9(\,:X?G=D)PANR-
MBXG24-/.W(5>9T;<#KJCS-45%%4_J!Q.?PG./_YKF)@R&^"H'QC="$+FG9'<
MV="Y189(NI,SW2;OO@C8N^XVN=$/>0NA(\\D8^^C1^GC[)-(Q,$%N""I' #@
M8^1#D,B0QG%D[4;Y.TP,T+;R(<0H 1>("'M5OS(.7EH OPC>(SCQB6B[)I:G
MR-J5CI'<A3 H:4^93?HMDZ(_8**@G S>@?80@V>L(:=+/0 0/[B$K#$;@G]\
M)AUR]6R872%^*S=!Y![\F.!='F"WW4&\M9.JO\P@8NO\0WB_^M)O*!H7\:+_
MQ@$P"T'J1_H ^!#X+[(^@8AR)^L?4]'QAG3([%%XA0]*\Q%"]JH9Y/ZTIQ!&
MH4)0Q'I0I$IC9'H+H6W!%W%L-!D?XA , TF9EX!G)!&(MW08@4'&MQ%'! #!
MHS@1P8'C!SH;HGAH9B?Q B4.F$4&87YYUQ#_@WX&%T-KUS^_ERLS" "V)T<&
M\4+Z(3ULXX,%H6T((4C#\S_] T>B,Q(_EPTB>"J?0Q#XL&\UT3-T%'D%43E&
MH7T1IWT*P7O9PS;EUD;/4PX1H4A#)X/F442A,X!QXGJP5W\-,CO8!H,60889
M!!+W!Q+)5Q/6-T@" 80C]!#R #E0]TQR%Q1B1Q$D_T<Z6J@0 /A7.\%Z!3%)
MYE$T#O&&0 <GT19[3V)[31A,>MA[]':*,E%WQH:*K-B*A*(/HM$"SN2*M%B+
M>2((O48EMKB+O.@FKT<E$F(AO3B,Q(@E]S A*NAFEB(B#C 7F?51!B81F\43
M#.$AB544_>5/U6%4^<%4..*,+K5DSZ5-L08CEE40J]5;MT40BX40'N)D5E83
MWEB-VJ$1U9%C6543S4B-!P%EY>A7)"(0^=%H/N9JK)@/LM@H@7(F@=(H;38A
M"?D )R!AXP"1FF%KF5&1L:@9$YF1%EE,%/F1KY<<36%3,R)>ZM@C8*$@1L41
M_?%D(")<X%B003*/]E2/$O_1:N.5%^$!5$WRCP7!73:Y73;5D@,!)#1V6289
M4[[UC361E!*!%@+08P91) 19C'V"D@0"4CM9%]U%5>'14?[X'3:U9T<Y%PVE
M($OR4N.(EE>2C@N1'4.)$#XU7O_D6 0!9<DU3_CH4WMI4P,& ' Y$5II:$A&
M(&%I$-714'\!E%CYF) 9F9(YF919F99YF9AY$&&B#>;!F4Z2)W;AF4'1E4U2
M9EFI(EU9E:()!)EYBJCEF5<I$"+BF0DV)FZA#0/&(Y[IF'MB#7(@FJE9$*0
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M.N. K4@E<$&BBU&[@MT$P>:F&!'W0-^IU.>=&2>(K-LPP=0'D=+P_ZT0&5U
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M.>>=>_XYZ*&+/CKII9M^.NJIJ[XZZZV[_CKLL<L^.^VUVWX[[KGKOON= 0$
!.P$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
